Canrenone: Difference between revisions
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 25: | Line 25: | ||
| routes_of_administration = | | routes_of_administration = | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | {{CMG}} | ||
==Overview== | |||
'''Canrenone''' ('''Contaren''', '''Luvion''') is an [[aldosterone antagonist]] with additional [[antiandrogen]] properties which is used as a [[diuretic]] in [[Europe]].<ref name="pmid15082604">{{cite journal |author=Romanelli RG, Gentilini P |title=Cross reactivity due to positive canrenone interference |journal=Gut |volume=53 |issue=5 |pages=772–3 |date=May 2004 |pmid=15082604 |pmc=1774040 |doi= |url=http://gut.bmj.com/cgi/pmidlookup?view=long&pmid=15082604}}</ref> | |||
It is a major [[active metabolite|active]] [[metabolite]] of [[spironolactone]], and is believed to be partially responsible for its effects. | |||
== See Also == | |||
* [[Potassium canrenoate]] | |||
* [[Spironolactone]] | |||
==References== | |||
{{reflist|2}} | |||
{{Antihypertensives and diuretics}} | {{Antihypertensives and diuretics}} | ||
[[Category: | [[Category:Diuretics]] | ||
[[Category:Drugs]] | [[Category:Cardiovascular Drugs]] | ||
[[Category:Drug]] | |||
[[Category:Aldosterone antagonists]] | |||
Latest revision as of 01:52, 25 July 2014
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C22H28O3 |
| Molar mass | 340.456 g/mol |
|
WikiDoc Resources for Canrenone |
|
Articles |
|---|
|
Most recent articles on Canrenone |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Canrenone at Clinical Trials.gov Clinical Trials on Canrenone at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Canrenone
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Canrenone Discussion groups on Canrenone Directions to Hospitals Treating Canrenone Risk calculators and risk factors for Canrenone
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Canrenone |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Canrenone (Contaren, Luvion) is an aldosterone antagonist with additional antiandrogen properties which is used as a diuretic in Europe.[1]
It is a major active metabolite of spironolactone, and is believed to be partially responsible for its effects.
See Also
References
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Diuretics
- Cardiovascular Drugs
- Drug
- Aldosterone antagonists